Clinical trial
Multicenter, Randomized, Phase II Trial of Neoadjuvant Hypofractionated Radiotherapy Plus Immunotherapy and First-line Therapy Versus Conventional Radiotherapy Plus First-line Therapy in pMMR Locally Recurrent Rectal Cancer (TORCH-R2)
NCT06928584 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multicenter, Randomized, Phase II Trial of Neoadjuvant Hypofractionated Radiotherapy Plus Immunotherapy and First-line Therapy Versus Conventional Radiotherapy Plus First-line Therapy in pMMR Locally Recurrent Rectal Cancer (TORCH-R2)
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- March 10, 2025
- Completion date
- March 10, 2030
- Enrollment
- 221 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally recurrent rectal cancer